- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04755855
Prospective Sinonasal Cancer Multi-institution Study
August 1, 2023 updated by: Carlos D. Pinheiro Neto, Mayo Clinic
Sinonasal Cancer Study to Evaluate Oncologic Outcomes and Quality of Life
This is a multi-institution prospective study of patients with sinonasal malignancies.
The goal of this study is to learn more about the course of sinonasal cancer, treatment outcomes, and patient quality of life.
In addition, central mutational and genomic analysis of tumor tissue will be evaluated.
Study Overview
Status
Recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Marissa Larson
- Phone Number: (507) 216-4999
- Email: larson.marissa@mayo.edu
Study Locations
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Recruiting
- Mayo Clinic in Rochester
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 month to 99 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients undergoing treatment for sinonasal cancers
Description
Inclusion Criteria:
- Subjects between the ages of 30 days (non-inclusive) and 99 years (inclusive)
- Patients with a diagnosis of sinonasal cancer
- Patients undergoing treatment at Mayo Clinic
Exclusion Criteria:
- Healthy individuals
- Unwilling to sign the informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Oncologic outcomes as measured by overall survival, disease specific survival and recurrence free survival
Time Frame: Through study completion, an average of 5 years
|
Through study completion, an average of 5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Quality of life outcomes including the University of Washington Quality of Life Questionnaire (UW-QOL v4) and the Sinonasal Outcome Test 22 (SNOT22)
Time Frame: Through study completion, an average of 5 years
|
Through study completion, an average of 5 years
|
Describe the molecular foundation of sinonasal malignancies utilizing RNA sequencing to identify transcriptomic tumor profiles
Time Frame: Through study completion, an average of 5 years
|
Through study completion, an average of 5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Carlos Pinheiro Neto, MD, PhD, Mayo Clinic
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2021
Primary Completion (Estimated)
January 1, 2031
Study Completion (Estimated)
January 1, 2031
Study Registration Dates
First Submitted
February 9, 2021
First Submitted That Met QC Criteria
February 12, 2021
First Posted (Actual)
February 16, 2021
Study Record Updates
Last Update Posted (Actual)
August 3, 2023
Last Update Submitted That Met QC Criteria
August 1, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 20-010181
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sinonasal Carcinoma
-
Dr. Victor H.F. LeeNot yet recruiting
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Merck Sharp & Dohme LLCRecruitingHPV-Related Squamous Cell Carcinoma | Sinonasal CarcinomaUnited States
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Regione LombardiaActive, not recruitingSinonasal TumorsItaly
-
University Hospital, ToulouseCompletedSinonasal PathologiesFrance
-
Fondazione IRCCS Istituto Nazionale dei Tumori,...Regione LombardiaActive, not recruitingUnresectable Sinonasal TumorsItaly
-
Vanderbilt University Medical CenterCompletedConditions Requiring Sinonasal SurgeryUnited States
-
Massachusetts General HospitalNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruitingMelanoma | Adenoid Cystic Carcinoma | Mucoepidermoid Carcinoma | Esthesioneuroblastoma | Squamous Cell Carcinoma | Sinonasal Carcinoma | Myoepithelial Carcinoma | Sinonasal Undifferentiated Carcinoma | Schneiderian CarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingLocally Advanced Chondrosarcoma | Metastatic Chondrosarcoma | Metastatic Sinonasal Adenocarcinoma | Locally Advanced Sinonasal Adenocarcinoma | Metastatic Large-cell Neuroendocrine Carcinoma | Locally Advanced Large-cell Neuroendocrine Carcinoma | Metastatic Olfactory Neuroblastoma | Locally Advanced... and other conditionsUnited States
-
Heidelberg UniversityCompletedSinonasal Malignancies | Adenocarcinoma and Squamous Cell Carcinoma of the Paranasal SinusesGermany
-
National Cancer Institute (NCI)Active, not recruitingHead and Neck Squamous Cell Carcinoma | Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Oral Cavity... and other conditionsUnited States